Compare Quest Diagnostics Inc (DGX) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Abrdn Physical Platinum Shares ETF trades at $14.75. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Abrdn Physical Platinum Shares ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| DGX | PPLT | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.02 | $25.23 |
52-Week Low | $166.42 | $11.78 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
PPLT trades at $14.52, down 1.69% with a bearish technical outlook showing 15 sell signals versus 0 buy signals. The ETF recently underwent a 1:10 stock split effective May 18, 2026, which adjusted share count without changing the fund's underlying value. Platinum has underperformed other precious metals recently, creating potential catch-up trade opportunities according to market commentary.
The outlook remains cautious as platinum lags gold's rally, though some analysts see long-term potential. Key risks include precious metals volatility and correlation dynamics. Recent downgrades to 'Hold' suggest limited near-term upside after PPLT's 84-100% returns over the past year, requiring careful entry timing for new positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
